Physician profile
Christopher J Marsh
NPI 1033428362
$9,162.21
in general payments reported to CMS, 2019-2025
30 companies · $3,070 in 2025
The $3,070 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $964 · 2022: $1,070 · 2023: $1,476 · 2024: $2,582 · 2025: $3,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,927 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,927.05 |
| Education | $200.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,284.65 | 2021-2025 | |
| Almirall LLC | $1,130.92 | 2021-2025 | Seysara |
| Lilly USA, LLC | $776.52 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $627.04 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $606.00 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $591.29 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $548.17 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $490.31 | 2022-2025 | Tremfya |
| Ucb, INC. | $392.19 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $353.20 | 2021-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $337.85 | 2021-2025 | Cabtreo, Siliq, Arazlo |
| Mayne Pharma Commercial LLC | $275.61 | 2021-2024 | |
| Galderma Laboratories, L.P. | $246.22 | 2024-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $223.65 | 2021-2025 | Winlevi, Ilumya |
| Epi Health, LLC | $160.74 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $154.56 | 2023-2024 | Vtama |
| Genzyme Corporation | $140.22 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $110.07 | 2024-2025 | Zoryve |
| Novo Nordisk INC | $107.63 | 2025 | Wegovy |
| Organon LLC | $104.78 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Amgen INC. | $71.43 | 2024-2025 | Otezla, Otezla |
| Journey Medical Corporation | $69.75 | 2021-2022 | |
| Incyte Corporation | $68.60 | 2021-2025 | Opzelura |
| Botanix Sb INC | $51.72 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $49.42 | 2021 | |
| Organogenesis INC. | $49.41 | 2023-2025 | Nushield, Puraply |
| Verrica Pharmaceuticals INC. | $30.88 | 2024 | Ycanth |
| Kerecis Limited | $25.03 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Dermira, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.